Compare Fiverr International Ltd (FVRR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Sanofi SA — how do they compare? Fiverr International Ltd trades at $8.74 (market cap $314.57M), while Sanofi SA trades at $43.62 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 331.6× Fiverr International Ltd's market cap, and Sanofi SA pays a 5.55% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals.
| FVRR | SNY | |
|---|---|---|
Market Cap | $314.57M | $104.30B |
Sector | Industrials | Health |
52-Week High | $26.67 | $52.34 |
52-Week Low | $8.75 | $41.33 |
Enterprise Value | $66.95M | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $8.71, down 4.18% over 24 hours, reflecting bearish technical signals and recent earnings misses. The stock shows attractive valuation multiples with a P/E of 10.8 and P/S of 0.77, while revenue grew to $430.91M in 2025. However, Q2 2026 results missed expectations, with revenue declining 10% year-over-year due to AI disruption pressures, as reported by MarketBeat on July 29, 2026.
The outlook remains cautious with significant AI-related headwinds compressing demand for freelance services. Near-term risks include execution challenges in a shifting competitive landscape, but the current low valuation may offer contrarian appeal if the company successfully adapts its strategy.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
